Objective: To investigate the outcomes of regorafenib treatment in refractory metastatic colorectal cancer (mCRC) patients by primary tumour sidedness, the e ects of previously targeted therapies, RAS status and in ammatory markers. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey, between January 2012 and September 2020. Methodology: Clinical data of 102 mCRC patients treated with regorafenib were compared according to the right and left colon subgroups, in terms of factors a ecting outcomes of regorafenib treatment. Kaplan-Meier method was used to identify factors associated with the overall survival. Results: Disease control rate (DCR) with regorafenib were similar in both right and left-sided colon tumours (60%vs. 61%, respectively, p>0.99). The median overall survival (OS) was 6.6 months in patients with right-sided colon cancers and 10.1 months in patients with left-sided colon cancers, but it was not signi cant (p=0.238). When evaluating by RAS status, there was an increase in favour of the right-sided mCRC in progression-free survival and OS, without statistical signi cance. In multivariate analysis, the patients with metastatic sites <3 and the number of prior systemic therapies d3 line had signi cantly higher survival. Conclusion: The tumour burden a ected the response to regorafenib in subsequent treatments and regorafenib was also e ective in heavily treated mCRC patients. There was no di erence in PFS and OS in terms of tumour sidedness by regorafenib treatment.